SOURCE: PlugMed Heart

PlugMed Heart

June 11, 2013 09:00 ET

PlugMed Will Present Promising Results From an in Vivo Study of the Osseointegrated Connector

PARIS--(Marketwired - Jun 11, 2013) -  


  • an opportunity to limit the risk of infection related to electric power drivelines for implantable Ventricular Assist Devices (VAD)
  • a major step toward the adoption of long-term circulatory support pumps to treat end-stage heart failure

PlugMed, a medical technology company, which designs and develops electrical energy transfer systems for implantable left ventricular assist devices (LVAD) and total artificial heart (TAH), will present promising results from an in vivo study at the 59th annual conference of ASAIO, a world reference in the field of artificial organs, in Chicago.

The study sets out to compare PlugMed's osseointegrated connector with the osseointegrated systems that have been used successfully for more than 30 years in the fields of maxillofacial surgery and ENT therapy. 

PlugMed's osseointegrated connector appears to significantly reduce episodes of infection, which remain one of the major obstacles to the development of long term circulatory support devices. These therapies represent a highly promising treatment for heart failure, a major cause of death in developed countries (637,000 deaths p.a. in Europe and almost 30,000 deaths p.a. in France).

Dr Steven Tsui, clinical director of the heart transplant service at the Papworth Hospital in Cambridge, a leading center for ventricular assist devices and for transplants in the UK, will present these results: "The study confirms the concept's feasibility. The bone-anchored connector is a promising solution for transferring energy to implanted circulatory support devices. Additionally, the results have enabled us to fine-tune the connector's design and turn the technology into a product that fits the needs of cardiac surgery."

Dr Pierre Sabin, President and Co-Founder of PlugMed, commented: "This presentation to the ASAIO is a major step in the validation of work conducted by PlugMed in collaboration with the maxillofacial surgery services of Professor Devauchelle in Amiens, and also several European cardiac surgery centers, including that of Professor Pascal Leprince at the
Pitié-Salpêtrière Hospital in Paris. The attention paid to our technology by the international scientific community has bolstered our strategy of giving priority to the heart pump market, before developing the products of our pipeline for other medical applications and artificial organs."

This presentation is scheduled for the "Cardiovascular Device Technology Abstracts" session, to be held June 13, 2013. Concurrently to this presentation to the ASAIO, a poster about the study will be presented at the 66th Congress of the SFCTCV (French Society for Thoracic and Cardiovascular Surgery), to be held in Marseille from June 12 to 15, 2013.

About the Electrical Osseointegrated Percutaneous Connector

The electrical osseointegrated percutaneous connector (or permanent electrical percutaneous connector) developed by PlugMed is based on technologies that have been successfully used in maxillofacial surgery and that establish lasting and safe percutaneous access, whatever the duration of the implantation.

Dr. Pierre Sabin, the inventor of the electrical osseointegrated percutaneous connector, first placed this technology in a human patient in an attempt to treat tinnitus. Conducted with a follow-up period of several years, this experimentation proved the feasibility of a permanent electrical percutaneous connector. In order to develop and market a connector adjusted to the needs of cardiac surgery, Dr. Pierre Sabin co-founded PlugMed.

About PlugMed

PlugMed is a medical technology company which designs and develops electrical connectors transferring energy from outside (batteries) to the inside of the body (artificial organs). Founded in 2010 by maxillofacial and cardiothoracic surgeons, the company is funded by the Ministry for Research, Oséo, the Région Haute-Normandie and private investors.

The company's first product is an electrical energy transfer system designed for implantable ventricular assist devices (VAD) and total artificial heart (TAH). By reducing dramatically the infection risk, PlugMed is to boost the adoption of VAD for advanced heart failure patients who are not eligible for heart transplant, a large underserved population.

As a gateway to the human body, the osseointegrated percutaneous connector technology by PlugMed should give birth to other ground-breaking medical devices.

For further information:

Press Release :

Contact Information